
OrsoBio to Unveil Liver-Targeted TLC-6740 Data at ADA’s 84th Scientific Sessions
OrsoBio, Inc., a clinical-stage biopharmaceutical company focused on treatments for obesity and associated disorders, has unveiled new data for its liver-targeted mitochondrial protonophore, TLC-6740, at the 84th Scientific Sessions of the American Diabetes Association in Orlando, Fla. The company will…












